On 16 and 17 May 2024, respectively, the Korea Biomedical Review reported that Korea’s Ministry of Food and Drug Safety approved MSD’s Keytruda® (pembrolizumab) for the following additional indications:
- locally advanced cervical cancer; and
- as an adjuvant after surgery for early-stage non-small cell lung cancer (NSCLC) in patients who have undergone resection and platinum-based chemotherapy.
The new cervical cancer approval is based on the KEYNOTE-A18 study and comes after MSD received Korean approval for Keytruda in April 2024 for patients with FIGO 2014 stage III-IVA cervical cancer in combination with chemotherapy.
The new NSCLC indication is based on the KEYNOTE-091 study and increases to six the number of on-label NSCLC indications for Keytruda in Korea.